Skip to main content
. 2012 Feb;74(1-2):105–114.

Table 1.

Clinical background characteristics of patients infected and not infected with extended-spectrum β-lactamase (ESBL)-producing E. coli

Variable ESBL (+)
n=14 (%)
ESBL (–)
n=14 (%)
P
Demographics
  Age (year): mean ± SD 72.1 ± 11.1 67.2 ± 16.7 *N.S.
  Gender: Number of males 8 (57.1) 8 (57.1) N.S.
  BMI (mean ± SD) 20.0 ± 3.7 19.9 ± 3.6 *N.S.
Comorbidities
  Respiratory disease 3 (21.4) 3 (21.4) N.S.
  Cardiovascular disease 3 (21.4) 2 (14.3) N.S.
  Hypertension 6 (42.9) 7 (50.0) N.S.
  Diabetes mellitus 5 (35.7) 6 (42.9) N.S.
  Renal disease 3 (21.4) 2 (14.3) N.S.
  Liver disease 0 (0) 0 (0) N.S.
  Malignant disease 9 (64.3) 8 (57.1) N.S.
  Use of corticosteroids 2 (14.3) 4 (28.6) N.S.
Hospital admission ward
  ICU 3 (21.4) 3 (21.4) N.S.
  Medical 8 (57.1) 6 (42.9) N.S.
  Surgical 3 (21.4) 5 (35.7) N.S.
Previous hospitalization within 3 months 3 (21.4) 5 (35.7) N.S.
Type of invasive device
  Urethral catheter 4 (28.6) 5 (35.7) N.S.
  Tracheal tube 2 (14.3) 2 (14.3) N.S.
  Central venous catheter 8 (57.1) 5 (35.7) N.S.
  Other 2 (14.3) 3 (21.4) N.S.
Infected regions
  Urine samples 6 (42.9) 5 (35.7) N.S.
  Respiratory samples 2 (14.3) 1 (7.1) N.S.
  Blood samples 1 (7.1) 2 (14.3) N.S.
  Stool samples 2 (14.3) 0 (0) N.S.
  Other samples 3 (21.4) 5 (35.7) N.S.
Days until detection of ESBL producer during hospitalization (mean ± SD) 36.4 ± 35.3 21.7 ± 12.5 *N.S.
Previous isolates
  Pseudomonas aeruginosa 3 (21.4) 3 (21.4) N.S.
  MRSA 2 (14.3) 1 (7.1) N.S.
  Candida 2 (14.3) 2 (14.3) N.S.

ESBL (+): patients infected with ESBL-producing E. coli; ESBL (–): patients not infected with ESBL-producing E. coli; N.S.: not significant; BMI: body mass index; ICU: intensive care unit; MRSA: methicillin-resistant Staphylococcus aureus. Renal disease was defined as having a serum creatinine level >2 mg/dL. All statistical tests were performed using Fisher’s exact test except for data indicated by *, for which Mann-Whitney U-test was used.